Powered by

Kala Presents Data Demonstrating Topical Delivery to Posterior Segment of the Eye

Jul 22, 2013 - Business Wire

Kala Pharmaceuticals, Inc., a leading developer of innovative products that rapidly and effectively penetrate the mucosal barrier to enable effective local treatment of ocular diseases, announced today the presentation of preclinical data which demonstrated that topical delivery of a small molecule receptor tyrosine kinase inhibitor (RTKi) formulated utilizing Kala's proprietary mucosal-penetrating particle (MPP) technology significantly enhanced drug levels in the retina. Drug levels in the fro...